Literature DB >> 30617907

Continuous subcutaneous apomorphine in advanced Parkinson's disease patients treated with deep brain stimulation.

Ángel Sesar1, Gustavo Fernández-Pajarín2, Begoña Ares2, José-Luis Relova3, Eduardo Arán4, María-Teresa Rivas2, Miguel Gelabert-González4, Alfonso Castro2.   

Abstract

INTRODUCTION: Deep brain stimulation (DBS) is an effective therapy for patients with advanced Parkinson's disease (PD). However, sometimes, it is not sufficient to adequately control motor symptoms. We describe our experience with continuous subcutaneous apomorphine infusion (APO) in patients with DBS.
METHODS: We undertook a retrospective analysis of all patients treated with DBS and APO at our centre over 12 years. Subjects were allocated to four groups: (1) APO temporarily before DBS, (2) APO after DBS complications before a new DBS, (3) APO after definitive DBS removal, and (4) APO in patients with DBS and declining response. Motor state and other parameters were analysed and compared for the different treatments.
RESULTS: Data for 71 patients were evaluated. Group 1: (n = 18) patients improved their motor function significantly with both APO and DBS (off-hours before APO 5.4 ± 1.4; after APO 1.4 ± 1.2, p > 0.001; after DBS 0.7 ± 0.8, p < 0.001). Group 2: (n = 11) patients were found to have mild but significant worsening of motor state between the first DBS treatment (off-hours 0.7 ± 1.0) and APO (2.2 ± 1.5, p = 0.02), and improvement between APO and the second DBS treatment (off-hours 0.6 ± 0.8, p = 0.03). Group 3: (n = 12) patients had mild but significant worsening of motor function between DBS (off-hours 1.1 ± 1.0) and APO (2.0 ± 0.9, p = 0.03). Group 4: (n = 13) significant improvement in motor function was observed between DBS alone (off-hours 3.9 ± 2.6) and DBS combined with APO (2.2 ± 1.3, p = 0.03).
CONCLUSION: In advanced PD, DBS may be not sufficient or may fail to control motor symptoms adequately. In these cases, APO, whether alone or in combination with DBS, is a good choice to improve the disease control.

Entities:  

Keywords:  Advanced Parkinson’s disease; Apomorphine; Deep brain stimulation; Treatment

Mesh:

Substances:

Year:  2019        PMID: 30617907     DOI: 10.1007/s00415-019-09184-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

1.  Parkinson's Disease Symptoms Associated with Developing On-State Axial Symptoms Early after Subthalamic Deep Brain Stimulation.

Authors:  Gustavo Fernández-Pajarín; Ángel Sesar; José Luis Relova; Begoña Ares; Isabel Jiménez; Miguel Gelabert-González; Eduardo Arán; Alfonso Castro
Journal:  Diagnostics (Basel)       Date:  2022-04-15

Review 2.  Combining Device-Aided Therapies in Parkinson's Disease: A Case Series and a Literature Review.

Authors:  Iro Boura; Nikolaos Haliasos; Ιrene-Areti Giannopoulou; Dimitrios Karabetsos; Cleanthe Spanaki
Journal:  Mov Disord Clin Pract       Date:  2021-05-19

Review 3.  Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

Authors:  Federico Carbone; Atbin Djamshidian; Klaus Seppi; Werner Poewe
Journal:  CNS Drugs       Date:  2019-09       Impact factor: 5.749

4.  Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson's disease: A prospective study of 22 patients.

Authors:  Gustavo Fernández-Pajarín; Ángel Sesar; Isabel Jiménez Martín; Begoña Ares; Alfonso Castro
Journal:  Clin Park Relat Disord       Date:  2021-12-24

5.  Continuous Subcutaneous Apomorphine Infusion before Subthalamic Deep Brain Stimulation: A Prospective, Comparative Study in 20 Patients.

Authors:  Gustavo Fernández-Pajarín; Ángel Sesar; Begoña Ares; Isabel Jiménez-Martín; Miguel Gelabert; Eduardo Arán-Echabe; José Luis Relova; Alfonso Castro
Journal:  Mov Disord Clin Pract       Date:  2021-10-09

Review 6.  Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?

Authors:  Silvia Rota; Daniele Urso; Daniel J van Wamelen; Valentina Leta; Iro Boura; Per Odin; Alberto J Espay; Peter Jenner; K Ray Chaudhuri
Journal:  Transl Neurodegener       Date:  2022-10-13       Impact factor: 9.883

Review 7.  The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?

Authors:  Joke M Dijk; Alberto J Espay; Regina Katzenschlager; Rob M A de Bie
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.